Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany. Show more

PAUL-EHRLICH-STRASSE 15-19, TÜBINGEN, GERMANY, 72076, Tübingen, 72076, USA

https://www.immatics.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

1.229B

52 Wk Range

$5.05 - $12.41

Previous Close

$8.99

Open

$9.05

Volume

1,607,924

Day Range

$8.92 - $9.57

Enterprise Value

732.2M

Cash

301.6M

Avg Qtr Burn

-42.73M

Insider Ownership

17.58%

Institutional Own.

79.71%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ACTengine® IMA203 GEN1 (PRAME) Details Cutaneous melanoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Anzu-Cel/Anzutresgene Autoleucel (IMA203) (TCR Cell Therapy) Details Metastatic Uveal Melanoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TCER® IMA402 (PRAME) Details Solid tumor/s, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Anzu-Cel/Anzutresgene Autoleucel (IMA203) (TCR Cell Therapy) Details Advanced Cutaneous Melanoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMA401/IMA402 (TCR Bispecific Combination) Details Squamous Non-Small Cell Lung Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACTengine® IMA203CD8 GEN2 (PRAME) Details Synovial Sarcoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACTengine® IMA203CD8 GEN2 (PRAME) Details Metastatic melanoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMA203CD8 (TCR Cell Therapy) Details Synovial Sarcoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACTengine® IMA203CD8 GEN2 (PRAME) Details Uterine Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACTengine® IMA203CD8 GEN2 (PRAME) Details Ovarian Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TCER® IMA401 (MAGEA4/8) Details Cancer, Solid tumor/s	Phase 1a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACTengine IMA202 Details Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACTengine IMA201 Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.